vs
Side-by-side financial comparison of ANAVEX LIFE SCIENCES CORP. (AVXL) and Spyre Therapeutics, Inc. (SYRE). Click either name above to swap in a different company.
Over the past eight quarters, ANAVEX LIFE SCIENCES CORP.'s revenue compounded faster (-21.6% CAGR vs -100.0%).
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical firm focused on developing novel small molecule therapeutics for neurodegenerative and neurodevelopmental disorders such as Alzheimer’s disease, Rett syndrome and Parkinson’s disease. It operates mainly across North America and European markets, targeting patients with high unmet medical needs.
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing targeted next-generation therapies for patients with rare, serious autoimmune and inflammatory diseases. It advances pipeline candidates through preclinical and early clinical stages to address unmet medical needs for global patient populations.
AVXL vs SYRE — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2024
| Metric | | |
|---|---|---|
| Revenue | $1.1M | $0 |
| Net Profit | $-5.7M | — |
| Gross Margin | — | — |
| Operating Margin | -628.5% | — |
| Net Margin | -526.5% | — |
| Revenue YoY | -22.6% | — |
| Net Profit YoY | 53.1% | — |
| EPS (diluted) | $-0.06 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.1M | — | ||
| Q3 25 | $999.0K | — | ||
| Q2 25 | $1.1M | — | ||
| Q1 25 | $1.2M | — | ||
| Q4 24 | $1.4M | $0 | ||
| Q3 24 | $1.8M | $0 | ||
| Q2 24 | $1.8M | $0 | ||
| Q1 24 | $1.8M | $0 |
| Q4 25 | $-5.7M | — | ||
| Q3 25 | $-9.8M | — | ||
| Q2 25 | $-13.2M | — | ||
| Q1 25 | $-11.2M | — | ||
| Q4 24 | $-12.1M | — | ||
| Q3 24 | $-11.6M | $-69.0M | ||
| Q2 24 | $-12.2M | $-38.8M | ||
| Q1 24 | $-10.5M | $-43.9M |
| Q4 25 | -628.5% | — | ||
| Q3 25 | -1085.5% | — | ||
| Q2 25 | -1345.0% | — | ||
| Q1 25 | -1034.1% | — | ||
| Q4 24 | -975.0% | — | ||
| Q3 24 | -810.9% | — | ||
| Q2 24 | -813.1% | — | ||
| Q1 24 | -718.9% | — |
| Q4 25 | -526.5% | — | ||
| Q3 25 | -983.7% | — | ||
| Q2 25 | -1231.9% | — | ||
| Q1 25 | -925.3% | — | ||
| Q4 24 | -868.8% | — | ||
| Q3 24 | -660.2% | — | ||
| Q2 24 | -680.1% | — | ||
| Q1 24 | -600.6% | — |
| Q4 25 | $-0.06 | — | ||
| Q3 25 | $-0.11 | — | ||
| Q2 25 | $-0.16 | — | ||
| Q1 25 | $-0.13 | — | ||
| Q4 24 | $-0.14 | — | ||
| Q3 24 | $-0.14 | $1.06 | ||
| Q2 24 | $-0.14 | $0.59 | ||
| Q1 24 | $-0.13 | $0.72 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $131.7M | $89.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $126.6M | $517.8M |
| Total Assets | $133.0M | $608.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $131.7M | — | ||
| Q3 25 | $102.6M | — | ||
| Q2 25 | $101.2M | — | ||
| Q1 25 | $115.8M | — | ||
| Q4 24 | $120.8M | $89.4M | ||
| Q3 24 | $132.2M | $71.6M | ||
| Q2 24 | $138.8M | $45.1M | ||
| Q1 24 | $139.4M | $227.6M |
| Q4 25 | $126.6M | — | ||
| Q3 25 | $94.9M | — | ||
| Q2 25 | $91.0M | — | ||
| Q1 25 | $99.8M | — | ||
| Q4 24 | $110.9M | $517.8M | ||
| Q3 24 | $120.3M | $327.4M | ||
| Q2 24 | $129.8M | $374.4M | ||
| Q1 24 | $135.0M | $152.3M |
| Q4 25 | $133.0M | — | ||
| Q3 25 | $103.8M | — | ||
| Q2 25 | $102.4M | — | ||
| Q1 25 | $117.1M | — | ||
| Q4 24 | $124.0M | $608.5M | ||
| Q3 24 | $135.6M | $421.1M | ||
| Q2 24 | $141.5M | $436.1M | ||
| Q1 24 | $144.5M | $487.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-7.2M | $-37.2M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-7.2M | — | ||
| Q3 25 | $-8.6M | — | ||
| Q2 25 | $-12.5M | — | ||
| Q1 25 | $-5.9M | — | ||
| Q4 24 | $-12.1M | $-37.2M | ||
| Q3 24 | $-6.7M | $-29.4M | ||
| Q2 24 | $-5.2M | $-62.2M | ||
| Q1 24 | $-11.7M | $-28.5M |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
